{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05754450",
            "orgStudyIdInfo": {
                "id": "AVTX-803-LAD-302"
            },
            "organization": {
                "fullName": "AUG Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II",
            "officialTitle": "A Phase 3, Open-Label, Extension Study to Assess the Long-term Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II (LAD II)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "an-extension-study-assessing-the-safety-and-efficacy-of-avtx-in-subjects-with-leukocyte-adhesion-deficiency-type-ii"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-06",
            "studyFirstSubmitQcDate": "2023-03-02",
            "studyFirstPostDateStruct": {
                "date": "2023-03-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-04",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "AUG Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG)."
        },
        "conditionsModule": {
            "conditions": [
                "Leukocyte Adhesion Deficiency"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 2,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "AVTX-803",
                    "type": "EXPERIMENTAL",
                    "description": "AVTX-803 at a dose specified by the investigator up to 5 times a day not to exceed 1700 mg/kg/day",
                    "interventionNames": [
                        "Drug: AVTX-803"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AVTX-803",
                    "description": "L-fucose crystalline powder",
                    "armGroupLabels": [
                        "AVTX-803"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of treatment emergent adverse events reported during the study attributable to AVTX-803.",
                    "timeFrame": "Through study completion, an average of 1 year."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Sialyl-Lewis X antigen expression on leukocytes",
                    "timeFrame": "At 6 months"
                },
                {
                    "measure": "Change from Baseline in the composite Nijmegen Pediatric Congenital Disorders of Glycosylation (CDG) Rating Scale (NPCRS)",
                    "description": "The NPCRS comprises 3 sections, with each section containing specific items relevant to the assessment of subjects with CDG. Section I (Current Function); Section II (System Specific Involvement); and Section III (Current Clinical Assessment). The sum of the scores is used to scale patients into 3 domains: mild (0-14), moderate (15-25), and severe (\\>26) category.",
                    "timeFrame": "Through study completion, an average of 1 year."
                },
                {
                    "measure": "Change from Baseline in the individual parameters of the Nijmegen Pediatric Congenital Disorders of Glycosylation (CDG) Rating Scale (NPCRS)",
                    "description": "The NPCRS comprises 3 sections, with each section containing specific items relevant to the assessment of subjects with CDG. Section I (Current Function); Section II (System Specific Involvement); and Section III (Current Clinical Assessment). The sum of the scores is used to scale patients into 3 domains: mild (0-14), moderate (15-25), and severe (\\>26) category.",
                    "timeFrame": "Through study completion, an average of 1 year."
                },
                {
                    "measure": "Goal Attainment Score (GAS)",
                    "description": "The parent (or subject) formulates 3 individual goals for improving quality of life. Typically, these goals affect mobility, independence, and disease-related health aspects. These goals will be re-evaluated and scored by the parent or subject at each study visit within a scale of -2 to +2.",
                    "timeFrame": "Through study completion, an average of 1 year."
                },
                {
                    "measure": "Clinician Global Impression of Severity (CGI-S)",
                    "description": "The CGI-S scale is a 7-point scale that assesses the severity of the subject's severity of disease/illness. 1=Normal, not ill at all; 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6= severely ill; 7=among the most extreme ill.\"",
                    "timeFrame": "Through study completion, an average of 1 year."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject must have completed protocol AVTX-803-LAD-301\n* Subject has biochemically and genetically proven LAD II (SLC35C1-CDG)\n\nExclusion Criteria:\n\n* Subject has severe anemia defined as hemoglobin \\<8.0 g/dL (\\<4.9 mmol/L)\n* Subject has impaired renal function as defined by an eGFR \\<90 mL/min\n* Subject has known or suspected intolerance or hypersensitivity to fucose or any ingredients of the investigational product\n* In the investigator's opinion, subject has a history of failure to respond to fucose at adequate dosing",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "6 Months",
            "maximumAge": "75 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Emily Cooke",
                    "role": "CONTACT",
                    "phone": "610.254.4201",
                    "email": "ecooke@avalotx.com"
                },
                {
                    "name": "Lisa Goldberg",
                    "role": "CONTACT",
                    "phone": "610.254.4201",
                    "email": "lgoldberg@avalotx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Garry Neil, MD",
                    "affiliation": "Avalo Therapeutics, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Eva Morava-Kozicz, MD PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000018370",
                    "term": "Leukocyte-Adhesion Deficiency Syndrome"
                },
                {
                    "id": "D000000267",
                    "term": "Tissue Adhesions"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002921",
                    "term": "Cicatrix"
                },
                {
                    "id": "D000005355",
                    "term": "Fibrosis"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000081207",
                    "term": "Primary Immunodeficiency Diseases"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000007153",
                    "term": "Immunologic Deficiency Syndromes"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3620",
                    "name": "Tissue Adhesions",
                    "asFound": "Adhesion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M20499",
                    "name": "Leukocyte-Adhesion Deficiency Syndrome",
                    "asFound": "Leukocyte Adhesion Deficiency",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6160",
                    "name": "Cicatrix",
                    "relevance": "LOW"
                },
                {
                    "id": "M8485",
                    "name": "Fibrosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M2285",
                    "name": "Primary Immunodeficiency Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10199",
                    "name": "Immunologic Deficiency Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3394",
                    "name": "Leukocyte Adhesion Deficiency Type 1",
                    "asFound": "Leukocyte Adhesion Deficiency",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}